| Bioactivity | Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas[1]. |
| Target | AXL. |
| Invitro | Tilvestamab (250 µM; 1 h) inhibits AXL phosphorylation in 786-0 cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model[1]. Animal Model: |
| Name | Tilvestamab |
| CAS | 2226775-26-2 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen TJ, et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol Rep. 2021 Dec;9(23):e15140. |